NASDAQ:TRAW Traws Pharma Q2 2026 Earnings Report $0.63 +0.00 (+0.16%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Traws Pharma EPS ResultsActual EPS-$0.16Consensus EPS -$0.34Beat/MissBeat by +$0.18One Year Ago EPSN/ATraws Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATraws Pharma Announcement DetailsQuarterQ2 2026Date8/14/2026TimeAfter Market ClosesConference Call DateFriday, August 14, 2026Conference Call Time4:00PM ETUpcoming EarningsTraws Pharma's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Traws Pharma Earnings HeadlinesTraws Pharma, Inc. (NASDAQ:TRAW) Given Consensus Recommendation of "Reduce" by BrokeragesSeptember 23, 2026 | americanbankingnews.comTraws Pharma (NASDAQ:TRAW) Trading 0% Higher - Should You Buy?September 23, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 30 at 1:00 AM | Stansberry Research (Ad)Traws Pharma shares rise after Q2 loss comes in better than expectedAugust 17, 2026 | finance.yahoo.comTraws Pharma Reports Q2 2026 Financial Results and Provides Business HighlightsAugust 14, 2026 | globenewswire.comTraws Pharma Announces New At-The-Market Offering ProgramJuly 10, 2026 | tipranks.comSee More Traws Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Traws Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Traws Pharma and other key companies, straight to your email. Email Address About Traws PharmaTraws Pharma (NASDAQ:TRAW) (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral infections and cancer. The company’s programs are focused on addressing diseases with significant unmet medical needs, and its candidates remain in clinical development rather than being marketed as approved products. Traws Pharma’s antiviral portfolio includes tivoxavir marboxil, an investigational oral treatment designed to inhibit the influenza virus cap-dependent endonuclease and potentially treat influenza A and B infections. The company is also developing oncology candidate narazaciclib, a next-generation cyclin-dependent kinase 4/6 inhibitor being studied for potential use in cancer treatment. The company was formerly known as Onconova Therapeutics, Inc. and adopted the Traws Pharma name as it expanded its focus to include respiratory antiviral development. Traws Pharma is headquartered in Newtown, Pennsylvania, and conducts research and clinical development activities intended to support potential treatment applications in international markets.View Traws Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
